98. Eosinophilic gastrointestinal disease Clinical trials / Disease details
Clinical trials : 171 / Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02722148 (ClinicalTrials.gov) | April 21, 2016 | 24/3/2016 | Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET) | Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET) | Eosinophilic Esophagitis | Device: Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy | University of North Carolina, Chapel Hill | National Institutes of Health (NIH) | Completed | 16 Years | 80 Years | All | 24 | N/A | United States |